Osimertinib is prescribed for:
- EGFR mutation-positive non-small cell lung cancer
- First-line treatment
- T790M resistance mutation
- Adjuvant treatment after surgery
- Oncology targeted therapy
Preferred first-line EGFR TKI due to CNS penetration.
Back to Medication Guide
Osimertinib
Generic Name: Osimertinib
Brand Names: Tagrisso
Osimertinib is a third-generation EGFR inhibitor for EGFR-mutated non-small cell lung cancer.
OncologyEGFR Inhibitor
What It's Used For
Side Effects
Common side effects:
- Diarrhea
- Rash
- Dry skin
- Paronychia (nail inflammation)
- Stomatitis
Serious side effects:
- Interstitial lung disease
- QT prolongation
- Cardiomyopathy
Additional Information
What is Osimertinib?
Osimertinib is a third-generation EGFR TKI that crosses the blood-brain barrier.
CNS Activity
Excellent brain penetration makes it effective for brain metastases - a common problem in lung cancer.
First-Line Preferred
Now preferred first-line treatment over earlier generation EGFR TKIs due to improved outcomes.
For more information, see MedlinePlus.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Ask Dr. Zimmer
Have questions about Osimertinib? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.